Cargando…
Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN
The transcription factor MYCN is frequently amplified and overexpressed in a variety of cancers including high-risk neuroblastoma (NB) and promotes tumor cell proliferation, survival, and migration. Therefore, MYCN is being pursued as an attractive therapeutic target for selective inhibition of its...
Autores principales: | Zhang, Xiaoling, Cong, Xianling, Jin, Xiangting, Liu, Yu’e, Zhang, Tong, Fan, Xinyuan, Shi, Xiyao, Zhang, Xiaoying, Wang, Xue, Yang, Yong-Guang, Dai, Xiangpeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404282/ https://www.ncbi.nlm.nih.gov/pubmed/37543638 http://dx.doi.org/10.1038/s41419-023-06030-5 |
Ejemplares similares
-
Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN
por: Shi, Xiyao, et al.
Publicado: (2022) -
CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma
por: Zhou, Yang, et al.
Publicado: (2023) -
An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability
por: Nagy, Zsuzsanna, et al.
Publicado: (2021) -
Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020) -
MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)